Engagements

Shire acquisition of Dyax

In the US, we advised counsel to Shire on its acquisition of Dyax, a small pharmaceutical company with pipeline products to treat hereditary angioedema (HAE). The deal, reviewed by the FTC, closed with no divestitures.

Related Capabilities

Meet Our Team